GPC-Rx

The company hopes to develop safer and more effective therapies, initially in the central nervous system and cardiovascular diseases. It has already gained a foothold in the pursuit of so-called "biased ligands" – GPCR-binding compounds that can selectively activate one (or a few) of the many biological pathways mediated by specific GPCR complexes.